secwatch.observer — SEC 8-K summary
======================================

Issuer:     CareDx, Inc. (CDNA)
CIK:        0001217234
Form:       8-K
Filed at:   2021-07-01T23:59:59+00:00
Accession:  0001193125-21-206325
Event type: leadership
Sentiment:  positive
Materiality: 0.50
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CareDx appoints Dr. Hannah Valantine to board; co-inventor of AlloSure technology
--------------------------------------------------------------------------------

- Dr. Hannah Valantine appointed as Class I director effective July 1, 2021.
- She is Professor of Medicine at Stanford and former NIH Chief Scientific Officer for Workforce Diversity.
- She co-invented the donor-derived cell-free DNA technology (AlloSure) for transplant rejection monitoring.
- Initial equity grants: option and RSU each with $150,000 grant-date fair value; annual cash retainer $40,000.
- She also serves on board of Pacific Biosciences of California (Nasdaq: PACB) since June 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1217234/000119312521206325/0001193125-21-206325-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1217234/000119312521206325/d196856d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-206325

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer